Premium
Germ cell testis cancer: 15‐year review
Author(s) -
Kelty Patrick,
Frazier Harold,
O'Connell Kevin,
Ghosh Bimal C.
Publication year - 1996
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199605)62:1<30::aid-jso7>3.0.co;2-s
Subject(s) - medicine , testicular cancer , cancer , cisplatin , germ cell tumors , germ cell , gynecology , surgery , oncology , chemotherapy , biochemistry , chemistry , gene
Testis cancer affects 2–3 men per every 100,000 in the United States, making it the most common solid tumor of men in the 20–35‐year‐old age range. Since the average age of active duty military personnel is included in the age range of those at greatest risk for germ cell testis cancer, it is of pertinent clinical importance to physicians who treat these young patients. The National Naval Medical Center has been using cisplatin‐based protocols since the time of their introduction. This study reviews the success of treating these patients and examines the treatment failures. © 1996 Wiley‐Liss, Inc.